Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:AKRX
CUSIP00972810
Phone847-279-6100
Debt
Debt-to-Equity Ratio1.01
Current Ratio4.64
Quick Ratio3.37
Price-To-Earnings
Trailing P/E Ratio9.70
Forward P/E Ratio29.38
P/E Growth1.28
Sales & Book Value
Annual Sales$841.04 million
Price / Sales2.32
Cash Flow$0.5246 per share
Price / Cash29.68
Book Value$6.65 per share
Price / Book2.34
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-24,550,000.00
Net Margins-12.22%
Return on Equity-9.63%
Return on Assets-4.20%
Miscellaneous
Employees2,308
Outstanding Shares125,260,000
Akorn (NASDAQ:AKRX) Frequently Asked Questions
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn (NASDAQ:AKRX) released its earnings results on Thursday, August, 4th. The company reported $0.58 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.55 by $0.03. The company earned $280.70 million during the quarter, compared to analysts' expectations of $272.99 million. Akorn had a negative return on equity of 9.63% and a negative net margin of 12.22%. The firm's revenue for the quarter was up 27.1% compared to the same quarter last year. View Akorn's Earnings History.
What price target have analysts set for AKRX?
6 analysts have issued 1-year price objectives for Akorn's stock. Their predictions range from $14.00 to $34.00. On average, they expect Akorn's stock price to reach $28.20 in the next year. View Analyst Ratings for Akorn.
Are investors shorting Akorn?
Akorn saw a drop in short interest during the month of May. As of May 15th, there was short interest totalling 10,488,176 shares, a drop of 16.6% from the April 30th total of 12,582,108 shares. Based on an average daily trading volume, of 4,564,948 shares, the days-to-cover ratio is presently 2.3 days. Approximately 11.3% of the company's shares are sold short. View Akorn's Current Options Chain.
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include SAGE Therapeutics (SAGE), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Loxo Oncology (LOXO), FibroGen (FGEN), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), Ultragenyx Pharmaceutical (RARE), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH) and Array Biopharma (ARRY).
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- Mr. Rajat Rai, Chief Exec. Officer (Age 51)
- Mr. Duane A. Portwood, Exec. VP & CFO (Age 52)
- Dr. Bruce Kutinsky, Chief Operating Officer (Age 52)
- Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Jonathan Kafer, Exec. VP of Sales & Marketing (Age 55)
Has Akorn been receiving favorable news coverage?
Media coverage about AKRX stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akorn earned a coverage optimism score of 0.10 on Accern's scale. They also gave news coverage about the company an impact score of 45.85 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Akorn's major shareholders?
Akorn's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.56%), Melqart Asset Management UK Ltd (1.11%), Dimensional Fund Advisors LP (0.93%), Gabelli Funds LLC (0.59%), Allianz Asset Management GmbH (0.56%) and Allianz Asset Management GmbH (0.56%). Company insiders that own Akorn stock include Brian Tambi, Bruce Kutinsky, John N Kapoor and Kenneth Abramowitz. View Institutional Ownership Trends for Akorn.
Which institutional investors are selling Akorn stock?
AKRX stock was sold by a variety of institutional investors in the last quarter, including OMERS ADMINISTRATION Corp, Allianz Asset Management GmbH, Allianz Asset Management GmbH, Cheyne Capital Management UK LLP, State of Wisconsin Investment Board, Gabelli Funds LLC, GABELLI & Co INVESTMENT ADVISERS INC. and Guggenheim Capital LLC. Company insiders that have sold Akorn company stock in the last year include Brian Tambi, Bruce Kutinsky and John N Kapoor. View Insider Buying and Selling for Akorn.
Which institutional investors are buying Akorn stock?
AKRX stock was bought by a variety of institutional investors in the last quarter, including Melqart Asset Management UK Ltd, Nexthera Capital LP, BlackRock Inc., Elo Mutual Pension Insurance Co, Ancora Advisors LLC, Alpine Associates Management Inc., PointState Capital LP and UBS Group AG. View Insider Buying and Selling for Akorn.
How do I buy shares of Akorn?
Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akorn's stock price today?
One share of AKRX stock can currently be purchased for approximately $15.57.
How big of a company is Akorn?
Akorn has a market capitalization of $1.96 billion and generates $841.04 million in revenue each year. Akorn employs 2,308 workers across the globe.
How can I contact Akorn?
Akorn's mailing address is 11925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]
MarketBeat Community Rating for Akorn (AKRX)
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
